TransCode raises ~$8M in private placement; expects to regain Nasdaq compliance

Transcode Therapeutics, Inc.

Issued 21.2M shares/pre-funded warrants, 21.2M Series C and 21.2M Series D warrants at $0.377/unit.
Warrants exercisable at $0.475; Series C 5-year term, Series D 2.5-year term after stockholder approval.
Gross proceeds ~$8M; proceeds for working capital and general corporate purposes.
Regained compliance with Nasdaq $2.5M minimum equity requirement after private placement; awaiting final determination.
Benchmark Company acted as exclusive placement agent; cash fee $50,000.

item 1.01 item 3.02 item 7.01 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.